Press Releases

BIA reaction to the EMA move to Amsterdam

BIA CEO Steve Bates responds on European Medicines Agency move from London to Amsterdam

BIA comment on Government response to the Accelerated Access Review

"Today’s government response to the Accelerated Access Review is a key piece in the jigsaw of UK government life science policy that will set the environment for our sector in the lead up to Brexit and beyond."

BIA announces new appointments to the BIA Board

Following the BIA AGM last week, the Association has announced the new members who have been elected to its Board.

UK on track to beat 2016 biotech venture capital fundraising and maintain European lead in 2017

The Biotech Financing Update, January-June 2017, offers an update on the figures from the annual finance report – ‘Building something great: UK’s Global bioscience cluster’ - that the BIA produced in conjunction with their data partner Informa Pharma Intelligence. This snapshot takes a look at the headline data for the first half of 2017 and will be updated in January 2018 when the full year data will be released.

 

Member News

£30k award for international 3Rs prize - competition now open

The annual international 3Rs award, sponsored by the NC3Rs and GlaxoSmithKline, recognises primary research which has made a significant contribution to advancing the 3Rs in medical, biological or veterinary sciences.

Cell and Gene Therapy Catapult research highlights the UK’s growing global leadership in innovative cell and gene therapy industry

New research revealed by the Cell and Gene Therapy (CGT) Catapult today, indicates that the UK cell and gene therapy industry continues to expand, as the UK establishes itself as a global leader in the development of living medicines.

Purolite Selects Repligen’s Market-Leading OPUS® Pre-Packed Columns

High-Performance Praesto® Protein A and Ion Exchange Chromatography Resins paired with Leading OPUS® Technology

Arecor strengthens the patent portfolio of its formulation technology for the development of novel vaccine and gene therapy products

• Notification of an ‘intention to grant’ patent protecting Arecor’s novel approach to enabling stable liquid adenovirus formulations, has been received from both the European and US patent offices

 

BIA blog

CEO Update: Monday 20 November

This is a big week for the sector and we expect the new location of the EMA to be announced later on today. We will keep members updated on all the news in our next Brexit webinar tomorrow. Losing the EMA is a bitter pill to swallow for the UK but it’s vital that the agency can continue to function wherever it is moved to. The focus must be on ensuring that there is a smooth transition to allow for this to happen so that we do not see a detrimental impact on the supply of medicines to patients in the UK and EU.

Video of the Week - 'Genomics: making sense of genetic information helping to improve healthcare'.

Genomics is about making sense of genetic information and using that to learn about human biology to improve the way we develop drugs and healthcare. Genomics plc was founded three years ago by four academics from the University of Oxford and wanted to help transform healthcare and they've now grown to over 30 people.

Sir John Bell at the UK Bioscience Forum

One of the many highlights of this year’s UK Bioscience Forum, held on October 12th, was Sir John Bell’s keynote speech. To an audience of 300 delegates from the world of UK bioscience, he gave what felt like a State of the Union address for the sector, extolling our strengths and recognising where there are challenges. Having only recently written and launched his highly anticipated Life Sciences Industrial Strategy, Sir John had a wealth of relevant advice and insight to share with the bioscience community, so what were the key take-home messages from the speech?

Searching for dementia treatments: Collaborating to speed up progress

It’s more than 100 years since Alzheimer's disease – the most common cause of dementia – was first discovered. It was in 1906 that Dr Alois Alzheimer identified the distinctive changes in the brain that we now know as the hallmarks of the disease. But it wasn’t until the late 1980s and early 1990s that breakthrough molecular and genetic research helped pinpoint one of the key biological processes behind the disease, a finding that has fuelled much of the drug discovery effort in Alzheimer’s over the last two to three decades.

 

Our publications

Influencing and shaping our sector, BIA update: July – October 2017

his quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from July to October 2017. Brexit, the government’s Industrial Strategy and a potential sector deal have been keeping all of us at the BIA very busy this quarter.

Growing the next generation of UK management talent

BIA directory of industry training opportunities to help build the next generation of management talent.

A vision for the UK life sciences sector in 2025

This vision, developed in consultation with the BIA Board and sector experts, sets out an ambitious goal for the UK to become a top global cluster in life sciences by 2025.